In a recent study, a combination therapy for the treatment of relapsed or refractory multiple myeloma proved to be as beneficial in routine clinical practice as it did in clinical trials used to support its approval.
A recent study sought to determine if clinical benefits of novel anticancer drugs have increased over time in conjunction with increasing costs.
A recent study compared the costs and toxicities of proton radiation, stereotactic body radiotherapy, and intensity-modulated radiotherapy for younger patients with prostate cancer.
The Institute for Clinical and Economic Review has announced plans to launch a new model transparency program for its drug assessment review process.
The ASCO Patient-Centered Oncology Payment model helps achieve costs savings in ovarian cancer when hospitalizations are reduced during the active treatment period.
In comparison to the funding and survival rate of many other cancer types, funding for ovarian, cervical, and uterine cancer does not align with their survival rates.
Following the dual-keynote presentations given by Ron Kline, MD, FAAP, and Lee N Newcomer, MD, MHA, a lively roundtable discussion took place on the NCCN stage regarding critical current and emerging issues in the delivery of cancer care in value-based care models.
The second presentation of the NCCN Annual Conference Keynote session was given by Lee N Newcomer, MD, MHA, a leading voice in the payer community, who spoke on cancer care delivery from the managed care perspective.
In the first presentation NCCN Annual Conference Keynote session, Ron Kline, MD, FAAP, gave an overview of the OCM and an unofficial preview of the preliminary data CMMI has accrued from OCM practices within the first 6 months of implementation.
Participation in clinical trials may help overcome health disparities in the treatment of advanced or recurrent ovarian cancer, according to a presentation at the SGO 2018 Annual Meeting on Women’s Cancer.